🚀 RECENT AI SUCCESS

Our AI successfully predicted the gap for $PLAY and executed a BUY strategy, securing a +29.52% net profit.

UPGRADE TO SEE LIVE SIGNALS

$22UA.DE

Biontech SE

European UnionEUROPEAN UNION
FREE PREVIEW
AVG HISTORICAL GAP0.00%
MAX GAP RECORD0.00%
PREMIUM
AI ACCURACY RATE
92.4%
Unlock AI Insights 🔓

LAST 10 EARNINGS GAPS (%)

VOLATILITY & BIAS PROFILE

AVG VOLATILITY0.0%
Bullish Gaps
Bearish Gaps
Neutral

Intelligence Brief

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany. Read full dossier

CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL